{
  "docId": "019de075-e1f8-726f-9315-81fdfad7abab",
  "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Spyre Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 37,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "The slide uses a stacked bar chart to visualize the additive clinical remission rates, noting a 22% delta between the individual components and the combination.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/29",
  "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab",
  "deckJsonHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab.json",
  "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.18,
        "y": 0.78
      },
      "kind": "callout",
      "text": "BLACK BOX WARNING",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08f8b663-b505-40eb-9f5f-59103d542da8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.68,
        "y": 0.78
      },
      "kind": "callout",
      "text": "PROBABLE BLACK BOX",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e106344-1a48-4fdd-81a7-97242323b3ee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.7,
        "x": 0.15,
        "y": 0.2
      },
      "kind": "chart",
      "text": "VEGA Combination Study (N=71/arm) showing 25% for Anti-TNF, 24% for Anti-IL23, and 47% for Combination (25% + 22% additive)",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68d073da-9888-4e64-a56b-b4b1047138be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.96,
        "x": 0.02,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "NOTE: In VEGA, only guselkumab (IL-23) was continued in maintenance for the combo arm in a treat-through design; Spyre plans to use combinations in maintenance. Maintenance remission rates for the anti-TNF arm, anti-IL23 arm, and induction combination arm were 28%, 31%, and 48%, respectively.; Feagan, B. G. et al. Lancet Gastroenterol. Hepatol. 8, 307–320 (2023).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82280c14-7d78-4c11-8424-6a0e91e056d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "JNJ's VEGA study demonstrated power of combination therapy despite relative weakness of components",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31634a81-5328-4aab-a74b-f4138da65f75",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chartjunk Elimination",
      "slug": "chartjunk-elimination",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "12644440-5739-45aa-966e-653f7977bf41",
      "evidence": "VEGA Combination Study (N=71/arm) showing 25% for Anti-TNF, 24% for Anti-IL23, and 47% for Combination (25% + 22% additive)",
      "confidence": 0.7
    },
    {
      "name": "Comparison frame",
      "slug": "comparison-frame",
      "agent": null,
      "layer": "slide",
      "matchId": "9f21dceb-c516-49b3-8ede-be7ac38d7b2b",
      "evidence": "VEGA Combination Study (N=71/arm) showing 25% for Anti-TNF, 24% for Anti-IL23, and 47% for Combination (25% + 22% additive)",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "6dd120f5-33e3-4ca6-a57c-f0a3ab9536dc",
      "evidence": "Comparing individual therapy performance against combination therapy performance.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}